RB every time you post - I'll post excerpts from SA articleYou would expect such a company to be valued at $150 million minimum. FROM SEEKING ALPHA ARTICLE>>>>> That's a minimum, most Phase III biotechs are valued much higher. Not so in this case: the market values Bioniche at a mere $25 million. This doesn't make any sense. Bioniche is so ridiculously undervalued - exceptionally low valuation for a Phase III biotech stock - that it could be today's most undervalued biotech stock on the market.